Cancer Vaccines Market Growth, Size, Trends, Demand, Revenue, Competition and Future Outlook

Global Cancer Vaccines Market Size- By Technology, By Type, By Indication, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Global Cancer Vaccines Market Size- By Technology, By Type, By Indication, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Published: Dec 2022 Report ID: HLCA2233 Pages: 1 - 242 Formats*:     
Category : Healthcare
Cancer Vaccines Market Introduction and Overview 

According to SPER Market Research, the Global Cancer Vaccines Market is estimated to reach USD 20.09 billion by 2032 with a CAGR of 12.82%.

The report includes an in-depth analysis of the Global Cancer Vaccines market, including market size and trends, product mix, distribution channels, and supplier analysis. Vaccines are medications that boost the body's immune system in order to defend it from outside intruders. Cancer vaccines are pharmaceuticals that modify biological responses. An immune system that has been activated eliminates foreign objects. The idea behind vaccines is that they help the body memorize foreign invaders so that they won't cause illness when they return. Biological response modifiers include cancer vaccinations. To fight disease, these modifiers work by triggering the immune system. Anxia Biosciences started the Phase Ib clinical study for its vaccine to prevent breast cancer in October 2022. The Department of Defence of the United States provided funding for this trial.

Market Opportunities and Challenges
The market for cancer vaccines is expanding as a result of a number of causes, including an increase in cancer diagnoses, rising government financing for the research of cancer vaccines, and technological advancements in the field. According to the recently released GLOBOCAN 2020 report from the International Agency for Research on Cancer, which estimated the incidence and mortality of 36 cancers in 185 countries worldwide, there were predicted to be 19,292,789 new cases of cancer diagnosed in 2020 and roughly 9,958,133 people worldwide passed away from cancer.

Cancer vaccines are generally expensive due to the extensive research and expenditure required for their production. The high cost of cancer vaccination may prevent patients from seeking treatment in economically depressed or disadvantaged areas. The expense may also discourage healthcare providers from providing immunization services at their facilities. As a result, the expense of the cancer vaccination operates primarily as a barrier to market expansion.

Cancer Vaccines Market


Market Competitive Landscape
The cancer vaccine industry is highly consolidated, with only a few big players. Partnerships, agreements, collaborations, mergers, and acquisitions are some of the growth methods used by market participants to increase their market position. The cancer vaccine industry is dominated by companies such as AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline, Roche.

Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2032
 Base year considered 2021
 Forecast period 2022-2032
 Segments coveredBy Technology, By Type, By Indication, By End User
 Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa
 Companies CoveredAduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, Dendreon, GlaxoSmithKline, Onco Thyreon, Oncovir, Oxford BioMedical, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech.
COVID-19 Impact on Global Cancer Vaccines Market
COVID-19 has had a limited impact on the Global Cancer Vaccines Market production and distribution firms, owing to shutdowns in various COVID-19 affected nations and an increase in the number of healthcare professionals becoming ill as a result of the pandemic, resulting in low supply. Due to shutdowns in numerous COVID-19-affected countries, the pandemic has impeded cancer vaccine production as well as the import and export of raw materials and finished items. The pandemic also propelled the market, owing to higher product approvals in emerging markets and leading industry players' increased attention on clinical research for the development of new vaccines. 

Key Target Audience:
  • Biopharmaceutical Companies
  • Clinical Researchers and Oncologists
  • Regulatory Authorities
  • Healthcare Providers
  • Patients and Caregivers
  • Investors and Funding Organizations
  • Academic and Research Institutions
  • Pharmaceutical Distributors and Suppliers
  • Cancer Advocacy Groups
Our in-depth analysis of the Cancer Vaccines Market includes the following segments:
By Type:
  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines
  • By Indication:
  • Cervical Cancer
  • Prostate Cancer
  • By End User:
  • Pediatrics
  • Adults
  • Key Topics Covered in the Report:
    • Global Cancer Vaccines Market Size (FY’2023-FY’2033)
    • Overview of Global Cancer Vaccines Market
    • Segmentation of Global Cancer Vaccines Market By Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines.)
    • Segmentation of Global Cancer Vaccines Market By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines.)
    • Segmentation of Global Cancer Vaccines Market By Indication (Cervical Cancer, Prostate Cancer Others.)
    • Segmentation of Global Cancer Vaccines Market By End User (Pediatrics, Adults.) 
    • Statistical Snap of Global Cancer Vaccines Market
    • Expansion Analysis of Global Cancer Vaccines Market
    • Problems and Obstacles in Global Cancer Vaccines Market
    • Competitive Landscape in the Global Cancer Vaccines Market
    • Impact of COVID-19 and Demonetization on Global Cancer Vaccines Market
    • Details on Current Investment in Global Cancer Vaccines Market
    • Competitive Analysis of Global Cancer Vaccines Market
    • Prominent Players in the Global Cancer Vaccines Market
    • SWOT Analysis of Global Cancer Vaccines Market
    • Global Cancer Vaccines Market Future Outlook and Projections (FY’2023-FY’2033)
    • Recommendations from Analyst
    1. Introduction
    1.1. Scope of the report
    1.2. Market segment analysis
     
    2. Research Methodology
    2.1 Research data source
    2.1.1 Secondary data
    2.1.2 Primary data
    2.1.3 SPER’s internal database
    2.1.4 Premium insight from KOL’s
    2.2 Market size estimation
    2.2.1 Top-down and Bottom-up approach
    2.3 Data triangulation
     
    3. Executive Summary
     
    4. Market Dynamics
    4.1. Driver, Restraint, Opportunity and Challenges analysis
    4.1.1 Drivers
    4.1.2 Restraints
    4.1.3 Opportunities
    4.1.4 Challenges 
    4.2. COVID-19 Impacts of the Global Cancer Vaccines Market 
     
    5. Market variables and outlook
    5.1. SWOT analysis 
    5.1.1 Strengths 
    5.1.2 Weaknesses 
    5.1.3 Opportunities
    5.1.4 Threats
    5.2. PESTEL analysis 
    5.2.1 Political landscape
    5.2.2 Economic landscape
    5.2.3 Social landscape 
    5.2.4 Technological landscape 
    5.2.5 Environmental landscape 
    5.2.6 Legal landscape 
    5.3. PORTER’S five forces analysis 
    5.3.1 Bargaining power of suppliers 
    5.3.2 Bargaining power of Buyers 
    5.3.3 Threat of Substitute 
    5.3.4 Threat of new entrant 
    5.3.5 Competitive rivalry
    5.4.Heat map analysis
     
    6. Global Cancer Vaccines Market, By Technology, 2019-2032 (USD Million)
    6.1. Antigen/Adjuvant Cancer Vaccines
    6.2. Dendritic Cells (DC) Cancer Vaccines
    6.3. Recombinant Cancer Vaccines
    6.4. Viral Vector & DNA Cancer Vaccines

    7. Global Cancer Vaccines Market, By Type, 2019-2032 (USD Million)
    7.1. Preventive Cancer Vaccines
    7.2. Therapeutic Cancer Vaccines 

    8. Global Cancer Vaccines Market, By Indication, 2019-2032 (USD Million)
    8.1. Cervical Cancer 
    8.2. Prostate Cancer 
    8.3. Others.

    9. Global Cancer Vaccines Market, By End User, 2019-2032 (USD Million)
    9.1. Pediatrics 
    9.2. Adults 

    10. Global Cancer Vaccines Market, By Region, 2019-2032 (USD Million)
    10.1. North America
    10.1.1. Canada
    10.1.2. Mexico
    10.1.3. United States
    10.2. Europe
    10.2.1. France
    10.2.2. Germany
    10.2.3. Italy
    10.2.4. Rest of Europe
    10.2.5. Spain
    10.2.6. United Kingdom
    10.3. Asia-Pacific
    10.3.1. Australia
    10.3.2. China
    10.3.3. India
    10.3.4. Japan
    10.3.5. Rest of Asia-Pacific
    10.3.6. South Korea
    10.4. South America
    10.4.1. Brazil
    10.4.2. Argentina
    10.4.3. Rest of South America
    10.5. Middle East & Africa
    10.5.1. Kingdom of Saudi Arabia 
    10.5.2. United Arab Emirates
    10.5.3. Rest of Middle East & Africa

    11. Company Profiles
    11.1. Aduro Biotech
    11.1.1. Company details
    11.1.2. Financial outlook
    11.1.3. Product summary
    11.1.4. Recent developments

    11.2. Advantagene
    11.2.1. Company details
    11.2.2. Financial outlook
    11.2.3. Product summary
    11.2.4. Recent developments

    11.3. Advaxis 
    11.3.1. Company details
    11.3.2. Financial outlook
    11.3.3. Product summary
    11.3.4. Recent developments

    11.4. Agenus
    11.4.1. Company details
    11.4.2. Financial outlook
    11.4.3. Product summary
    11.4.4. Recent developments

    11.5. Altor BioScience
    11.5.1. Company details
    11.5.2. Financial outlook
    11.5.3. Product summary
    11.5.4. Recent developments

    11.6. Argos Therapeutics
    11.6.1. Company details
    11.6.2. Financial outlook
    11.6.3. Product summary
    11.6.4. Recent developments

    11.7. Dendreon
    11.7.1. Company details
    11.7.2. Financial outlook
    11.7.3. Product summary
    11.7.4. Recent developments

    11.8. GlaxoSmithKline
    11.8.1. Company details
    11.8.2. Financial outlook
    11.8.3. Product summary
    11.8.4. Recent developments

    11.9. OncoThyreon
    11.9.1. Company details
    11.9.2. Financial outlook
    11.9.3. Product summary
    11.9.4. Recent developments

    11.10. Oncovir 
    11.10.1. Company details
    11.10.2. Financial outlook
    11.10.3. Product summary
    11.10.4. Recent developments

    11.11. Oxford BioMedical
    11.11.1. Company details
    11.11.2. Financial outlook
    11.11.3. Product summary
    11.11.4. Recent developments

    11.12. Prsima BioMed
    11.12.1. Company details
    11.12.2. Financial outlook
    11.12.3. Product summary
    11.12.4. Recent developments

    11.13. Sotio
    11.13.1. Company details
    11.13.2. Financial outlook
    11.13.3. Product summary
    11.13.4. Recent developments

    11.14. Transgene
    11.14.1. Company details
    11.14.2. Financial outlook
    11.14.3. Product summary
    11.14.4. Recent developments

    11.15. Ubivac
    11.15.1. Company details
    11.15.2. Financial outlook
    11.15.3. Product summary
    11.15.4. Recent developments

    11.16. Vaccinogen
    11.16.1. Company details
    11.16.2. Financial outlook
    11.16.3. Product summary
    11.16.4. Recent developments

    11.17. Vaxon Biotech
    11.17.1. Company details
    11.17.2. Financial outlook
    11.17.3. Product summary
    11.17.4. Recent developments

    SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

    The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

    SPER-Methodology-1

    SPER-Methodology-2

    SPER-Methodology-3


    Frequently Asked Questions About This Report
    The Cancer Vaccines Market is projected to reach USD 20.09 billion by 2032, growing at a CAGR of 12.82% during the forecast period.
    The Cancer Vaccines Market grew in market size from 2021. The Market is expected to reach USD 20.09 billion by 2032, at a CAGR of 12.82% during the forecast period.
    The Cancer Vaccines Market CAGR of 12.82% during the forecast period.
    You can get the sample pages by clicking the link -Click Here
    The Cancer Vaccines Market size is USD 20.09 billion from 2022 to 2032.
    The Cancer Vaccines Market segment is Covered By Technology, By Type, By Indication, By End User.
    The North America and Europe region is anticipated to have the highest market share in the Cancer Vaccines Market.
    The key players in the market include Companies Covered Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, Dendreon, GlaxoSmithKline, Onco Thyreon, Oncovir, Oxford BioMedical, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech.
    Cancer vaccines are classified as biological response modifiers. These modifiers function by activating the immune system to combat illness. Broadly, cancer vaccines are of two types: prevention vaccines and treatment vaccines. In order to prevent cancer, healthy people are given preventive cancer vaccinations.
    Not able to find what you are looking for? Need customization in the existing report?
    Click Here
    PLACE AN ORDER
    • 15% off
       
      $ 4250
    • 20% off
               
      $ 5650
    • 25% off
           
      $ 7450
    Pre-Purchase Inquiry
    SEND AN INQUIRY
    NEED CUSTOMIZATION?
    Request Customization
    CALL OR EMAIL US
    US:
    India:
    Email:
    100% Secure Payment

    SPER American Express
    SPER VISA
    SPER Master Card
    SPER Mestro
    SPER Paypal
    SPER CCAvenues

    Join Our SPER Panel

    Our Global Clients

    Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
    SPER-Astellas Pharma
    SPER-Citi Bank
    SPER-Microsoft
    SPER-EY
    SPER-McKinsey
    SPER-Bain
    SPER-Max-Healthcare
    SPER-DHL
    SPER-SIEMENS
    SPER-IQVIA
    SPER-Pfizer
    SPER-LOREAL
    SPER-Kankar IMRB
    SPER-ITA
    SPER-PWC
    SPER-Sanofi
    SPER-p&g
    SPER-Johnson & Johnson
    SPER-IPSOS
    SPER-Heineken

    SPER

    Market Research

    We are the leading, full-service global market research and consulting company.

    Certificates
    iso-1 iso-1 iso-1 ESOMAR
    Secure Payments
    SPER Payment Options
    Contact HR

     [email protected]

     +91-742-898-5650